Trial Profile
Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes (DILfrequency)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 Oct 2022
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms DILfrequency
- 20 Sep 2016 Status changed from active, no longer recruiting to completed.
- 21 Jun 2016 UKCRN reports status as Completed, Status retained as active no longer recruiting as per NCT
- 02 Jun 2016 Status changed from recruiting to active, no longer recruiting.